SCHEMBL5028332

SCHEMBL5028332

CO[C@]1(C)O[C@H]2[C@H](OCc3ccccc3)O[C@H](CO)[C@H](O)[C@@H]2O[C@@]1(C)OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.44
GSTP1 P09211 2/20 0.44
LGALS8 O00214 1/20 0.43
SYNJ2 O15056 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ABL1 P00519 1/20 0.41
ALPL P05186 1/20 0.41
POLB P06746 1/20 0.41
ALPI P09923 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
ALPG P10696 1/20 0.41
PABPC1 P11940 1/20 0.41
RECQL P46063 1/20 0.41
GALK1 P51570 1/20 0.41
CASP7 P55210 1/20 0.41
CASP6 P55212 1/20 0.41
MCL1 Q07820 1/20 0.41
RIN1 Q13671 1/20 0.41
EIF4H Q15056 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5032427 1.00 SLC6A2 (0.44) SLC6A2GSTP1LGALS8SYNJ2KDM4E
SCHEMBL13775014 0.91 GSTP1 (0.44) SLC6A2GSTP1LGALS8SYNJ2KDM4E
SCHEMBL14747391 0.91 GSTP1 (0.44) SLC6A2GSTP1LGALS8SYNJ2KDM4E
SCHEMBL4173508 0.91 GSTP1 (0.44) SLC6A2GSTP1LGALS8SYNJ2KDM4E
SCHEMBL5026166 0.91 GSTP1 (0.44) SLC6A2GSTP1LGALS8SYNJ2KDM4E
SCHEMBL7155860 0.81 SLC6A2 (0.52) SLC6A2LGALS8SYNJ2KDM4EABL1
SCHEMBL7148182 0.81 SLC6A2 (0.52) SLC6A2LGALS8SYNJ2KDM4EABL1
SCHEMBL7149909 0.81 SLC6A2 (0.52) SLC6A2LGALS8SYNJ2KDM4EABL1
SCHEMBL7644769 0.81 SLC6A2 (0.52) SLC6A2LGALS8SYNJ2KDM4EABL1
SCHEMBL6704224 0.80 SLC6A2 (0.41) SLC6A2LGALS8PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389565-B2 Antidiabetic agents; controlling carbohydrate metabolism SIMON FRASER UNIVERSITY (CA) 2013-03-05 US disclosed
US-8389565-B2 Antidiabetic agents; controlling carbohydrate metabolism SIMON FRASER UNIVERSITY (CA) 2013-03-05 US disclosed
EP-1999124-A1 GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME SIMON FRASER UNIVERSITY (CA) 2008-12-10 EP disclosed
WO-2007098597-A1 GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME SIMON FRASER UNIVERSITY (CA) 2007-09-07 WO disclosed
US-20060247222-A1 Glycosidase inhibitors and methods of synthesizing same SIMON FRASER UNIVERSITY (CA) 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247222-A1 Glycosidase inhibitors and methods of synthesizing same STS, SCLY, MGAM SLC6A2 404/4885GSTP1 857/4885LGALS8 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.